Chemical: Drug
sunitinib

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


Annotated Labels

  1. FDA Label for sunitinib
  2. EMA Label for sunitinib and CYP3A4

1. FDA Label for sunitinib

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Asthenia
    • Adverse reactions section
    • source: PHONT
  • Carcinoma, Renal Cell
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Diarrhea
    • Adverse reactions section
    • source: PHONT
  • Fatigue
    • Adverse reactions section
    • source: PHONT
  • Gastrointestinal Stromal Tumors
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Hypertension
    • Warnings section, Adverse reactions section
    • source: PHONT
  • Neoplasms
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Neutropenia
    • Adverse reactions section
    • source: PHONT

last updated 09/16/2014

2. EMA Label for sunitinib and CYP3A4

Informative PGx

Genes and/or phenotypes found in this label

  • CYP3A4
    • metabolism/PK, Dosage & administration section, Drug interactions section, Pharmacokinetics section, Warnings and precautions section
    • source: European Medicines Agency

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for sunitinib

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA ABCB1 *1 N/A N/A N/A
No VIP available CA VA ABCB1 *2 (PMID: 11503014) N/A N/A N/A
No VIP available No VIP available VA ABCB1 *2 (PMID: 12893986) N/A N/A N/A
No VIP available No VIP available VA CYP3A4 *1 N/A N/A N/A
No VIP available No VIP available VA CYP3A4 *22 N/A N/A N/A
No VIP available No VIP available VA CYP3A5 *1A N/A N/A N/A
No VIP available No VIP available VA CYP3A5 *3A N/A N/A N/A
No VIP available CA VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available No Clinical Annotations available VA
rs1048943 NC_000015.10:g.74720644T>C, NC_000015.9:g.75012985T>C, NG_008431.1:g.3103T>C, NM_000499.3:c.1384A>G, NM_000499.4:c.1384A>G, NM_001319216.1:c.1297A>G, NM_001319217.1:c.1384A>G, NP_000490.1:p.Ile462Val, NP_001306145.1:p.Ile433Val, NP_001306146.1:p.Ile462Val, XM_005254185.1:c.1384A>G, XM_005254186.1:c.1384A>G, XM_005254187.1:c.1300A>G, XM_005254188.1:c.1297A>G, XM_005254189.1:c.601A>G, XP_005254242.1:p.Ile462Val, XP_005254243.1:p.Ile462Val, XP_005254244.1:p.Ile434Val, XP_005254245.1:p.Ile433Val, XP_005254246.1:p.Ile201Val, rs17861092, rs3188998, rs386513458, rs52810784
T > C
SNP
I462V
No VIP available CA VA
rs1126647 NC_000004.11:g.74609045A>T, NC_000004.12:g.73743328A>T, NG_029889.1:g.7823A>T, NM_000584.3:c.*864A>T, rs11545233, rs17296307, rs2227547, rs2298879, rs3181782
A > T
SNP
No VIP available CA VA
rs1128503 NC_000007.13:g.87179601A>G, NC_000007.14:g.87550285A>G, NG_011513.1:g.167964T>C, NM_000927.4:c.1236T>C, NP_000918.2:p.Gly412=, rs116989428, rs17276907, rs2032587, rs2229105, rs28365046, rs386518005, rs58257317
A > G
SNP
G412G
No VIP available No Clinical Annotations available VA
rs11762213 NC_000007.13:g.116339282G>A, NC_000007.14:g.116699228G>A, NG_008996.1:g.31824G>A, NM_000245.2:c.144G>A, NM_001127500.1:c.144G>A, NP_000236.2:p.Ala48=, NP_001120972.1:p.Ala48=, XM_005250353.1:c.201G>A, XM_006715991.2:c.-91+26651G>A, XM_011516223.1:c.201G>A, XP_005250410.1:p.Ala67=, XP_011514525.1:p.Ala67=
G > A
SNP
A48A
No VIP available No Clinical Annotations available VA
rs1799939 NC_000010.10:g.43610119G>A, NC_000010.11:g.43114671G>A, NG_007489.1:g.42603G>A, NM_020630.4:c.2071G>A, NM_020975.4:c.2071G>A, NP_065681.1:p.Gly691Ser, NP_066124.1:p.Gly691Ser, XM_011540027.1:c.2071G>A, XP_011538329.1:p.Gly691Ser, rs17362555, rs17845010, rs17857772, rs3781260
G > A
SNP
G691S
No VIP available CA VA
rs1800925 NC_000005.10:g.132657117C>T, NC_000005.9:g.131992809C>T, NG_012090.1:g.3945C>T, NM_002188.2:c.-1070C>T, NR_132125.1:n.-963G>A, NR_132126.1:n.-1225G>A, XR_246587.1:n.-1225G>A, rs3777375, rs4134673, rs60620226
C > T
SNP
No VIP available No Clinical Annotations available VA
rs1870377 NC_000004.11:g.55972974T>A, NC_000004.12:g.55106807T>A, NG_012004.1:g.23789A>T, NM_002253.2:c.1416A>T, NP_002244.1:p.Gln472His, rs52810770
T > A
SNP
Q472H
No VIP available CA VA
rs1933437 NC_000013.10:g.28624294G>A, NC_000013.11:g.28050157G>A, NG_007066.1:g.55412C>T, NM_004119.2:c.680C>T, NP_004110.2:p.Thr227Met, NR_130706.1:n.762C>T, XM_005266318.1:c.680C>T, XM_005266319.1:c.680C>T, XM_011535015.1:c.623C>T, XM_011535016.1:c.155C>T, XM_011535017.1:c.155C>T, XM_011535018.1:c.155C>T, XP_005266375.1:p.Thr227Met, XP_005266376.1:p.Thr227Met, XP_011533317.1:p.Thr208Met, XP_011533318.1:p.Thr52Met, XP_011533319.1:p.Thr52Met, XP_011533320.1:p.Thr52Met, rs52828701, rs57444997
G > -
G > A
SNP
T227M
No VIP available No Clinical Annotations available VA
rs2010963 NC_000006.11:g.43738350C>G, NC_000006.12:g.43770613C>G, NG_008732.1:g.5398C>G, NM_001025366.2:c.-94C>G, NM_001025367.2:c.-94C>G, NM_001025368.2:c.-94C>G, NM_001025369.2:c.-94C>G, NM_001025370.2:c.-94C>G, NM_001033756.2:c.-94C>G, NM_001171622.1:c.-94C>G, NM_001171623.1:c.-634C>G, NM_001171624.1:c.-634C>G, NM_001171625.1:c.-634C>G, NM_001171626.1:c.-634C>G, NM_001171627.1:c.-634C>G, NM_001171628.1:c.-634C>G, NM_001171629.1:c.-634C>G, NM_001171630.1:c.-634C>G, NM_001204384.1:c.-634C>G, NM_001204385.1:c.-94C>G, NM_001287044.1:c.-1507C>G, NM_001317010.1:c.-634C>G, NM_003376.5:c.-94C>G, XM_005249363.1:c.-1507C>G
C > G
SNP
No VIP available CA VA
rs2032582 NC_000007.13:g.87160618A>C, NC_000007.13:g.87160618A>T, NC_000007.14:g.87531302A>C, NC_000007.14:g.87531302A>T, NG_011513.1:g.186947T>A, NG_011513.1:g.186947T>G, NM_000927.4:c.2677T>A, NM_000927.4:c.2677T>G, NP_000918.2:p.Ser893Ala, NP_000918.2:p.Ser893Thr, rs10228331, rs2229106, rs386553610, rs57135550, rs9641018
A > C
SNP
S893A
No VIP available No Clinical Annotations available VA
rs20541 NC_000005.10:g.132660272A>G, NC_000005.9:g.131995964A>G, NG_012090.1:g.7100A>G, NM_002188.2:c.431A>G, NP_002179.2:p.Gln144Arg, rs17166139, rs17772737, rs386555165, rs57467283
A > G
SNP
Q144R
No VIP available No Clinical Annotations available VA
rs2070744 NC_000007.13:g.150690079C=, NC_000007.13:g.150690079C>T, NC_000007.14:g.150992991C=, NC_000007.14:g.150992991C>T, NG_011992.1:g.6933C=, NG_011992.1:g.6933C>T, NM_000603.4:c.-51-762C=, NM_000603.4:c.-51-762C>T, NM_001160109.1:c.-813C=, NM_001160109.1:c.-813C>T, NM_001160110.1:c.-813C=, NM_001160110.1:c.-813C>T, NM_001160111.1:c.-813C=, NM_001160111.1:c.-813C>T, XM_006716002.2:c.-813C=, XM_006716002.2:c.-813C>T, rs10333298, rs34629525, rs61324345
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2231137 NC_000004.11:g.89061114C>T, NC_000004.12:g.88139962C>T, NG_032067.2:g.96361G>A, NM_001257386.1:c.34G>A, NM_004827.2:c.34G>A, NP_001244315.1:p.Val12Met, NP_004818.2:p.Val12Met, XM_005263354.1:c.34G>A, XM_005263354.2:c.34G>A, XM_005263355.1:c.34G>A, XM_005263355.2:c.34G>A, XM_005263356.1:c.34G>A, XM_005263356.2:c.34G>A, XM_011532420.1:c.34G>A, XP_005263411.1:p.Val12Met, XP_005263412.1:p.Val12Met, XP_005263413.1:p.Val12Met, XP_011530722.1:p.Val12Met
C > T
SNP
V12M
No VIP available CA VA
rs2231142 NC_000004.11:g.89052323G>T, NC_000004.12:g.88131171G>T, NG_032067.2:g.105152C>A, NM_001257386.1:c.421C>A, NM_004827.2:c.421C>A, NP_001244315.1:p.Gln141Lys, NP_004818.2:p.Gln141Lys, XM_005263354.1:c.421C>A, XM_005263354.2:c.421C>A, XM_005263355.1:c.421C>A, XM_005263355.2:c.421C>A, XM_005263356.1:c.421C>A, XM_005263356.2:c.421C>A, XM_011532420.1:c.421C>A, XP_005263411.1:p.Gln141Lys, XP_005263412.1:p.Gln141Lys, XP_005263413.1:p.Gln141Lys, XP_011530722.1:p.Gln141Lys, rs12721641, rs28365035, rs3736117, rs52809243, rs58973676
G > T
SNP
Q141K
No VIP available No Clinical Annotations available VA
rs2276707 NC_000003.11:g.119534153C>T, NC_000003.12:g.119815306C>T, NG_011856.1:g.39823C>T, NM_003889.3:c.938-17C>T, NM_022002.2:c.1055-17C>T, NM_033013.2:c.827-17C>T, XM_005247866.1:c.773-17C>T, rs60905954
C > G
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2305948 NC_000004.11:g.55979558C>T, NC_000004.12:g.55113391C>T, NG_012004.1:g.17205G>A, NM_002253.2:c.889G>A, NP_002244.1:p.Val297Ile, rs386564519, rs52830740, rs56532927, rs56973163
C > T
SNP
V297I
No VIP available No Clinical Annotations available VA
rs2307424 NC_000001.10:g.161202605G>A, NC_000001.11:g.161232815G>A, NG_029113.1:g.10396C>T, NM_001077469.2:c.540C>T, NM_001077470.2:c.453C>T, NM_001077471.2:c.540C>T, NM_001077472.2:c.453C>T, NM_001077473.2:c.453C>T, NM_001077474.2:c.540C>T, NM_001077475.2:c.453C>T, NM_001077476.2:c.453C>T, NM_001077477.2:c.453C>T, NM_001077478.2:c.540C>T, NM_001077479.2:c.453C>T, NM_001077480.2:c.540C>T, NM_001077481.2:c.540C>T, NM_001077482.2:c.540C>T, NM_005122.4:c.540C>T, NP_001070937.1:p.Pro180=, NP_001070938.1:p.Pro151=, NP_001070939.1:p.Pro180=, NP_001070940.1:p.Pro151=, NP_001070941.1:p.Pro151=, NP_001070942.1:p.Pro180=, NP_001070943.1:p.Pro151=, NP_001070944.1:p.Pro151=, NP_001070945.1:p.Pro151=, NP_001070946.1:p.Pro180=, NP_001070947.1:p.Pro151=, NP_001070948.1:p.Pro180=, NP_001070949.1:p.Pro180=, NP_001070950.1:p.Pro180=, NP_005113.1:p.Pro180=, XM_005245693.1:c.756C>T, XM_005245693.3:c.756C>T, XM_005245694.1:c.756C>T, XM_005245694.3:c.756C>T, XM_005245695.1:c.756C>T, XM_005245696.1:c.666C>T, XM_005245697.1:c.540C>T, XM_005245697.3:c.540C>T, XM_005245698.1:c.455-1341C>T, XM_005245699.1:c.455-1341C>T, XM_011510237.1:c.756C>T, XP_005245750.1:p.Pro252=, XP_005245751.1:p.Pro252=, XP_005245752.1:p.Pro252=, XP_005245753.1:p.Pro222=, XP_005245754.1:p.Pro180=, XP_011508539.1:p.Pro252=, rs58418822
G > A
SNP
P180P
No VIP available No Clinical Annotations available VA
rs2981582 NC_000010.10:g.123352317A>G, NC_000010.11:g.121592803A>G, NG_012449.1:g.10656T>C, NM_000141.4:c.109+906T>C, NM_001144913.1:c.109+906T>C, NM_001144914.1:c.109+906T>C, NM_001144915.1:c.109+906T>C, NM_001144916.1:c.109+906T>C, NM_001144917.1:c.109+906T>C, NM_001144918.1:c.109+906T>C, NM_001144919.1:c.109+906T>C, NM_022970.3:c.109+906T>C, NM_023029.2:c.109+906T>C, NR_073009.1:n.756+906T>C, XM_006717708.2:c.166+906T>C, XM_006717709.2:c.166+906T>C, XM_006717710.2:c.166+906T>C, XM_006717711.2:c.166+906T>C, XM_006717712.2:c.166+906T>C, XM_006717713.2:c.166+906T>C, rs45631640, rs56718061
A > G
SNP
No VIP available CA VA
rs307821 NC_000005.10:g.180603313C>A, NC_000005.9:g.180030313C>A, NG_011536.1:g.51312G>T, NM_182925.4:c.3971G>T, NP_891555.2:p.Arg1324Leu, XM_011534477.1:c.4220G>T, XM_011534478.1:c.4202G>T, XM_011534479.1:c.*117G>T, XM_011534482.1:c.3989G>T, XM_011534483.1:c.3911G>T, XM_011534484.1:c.3512G>T, XP_011532779.1:p.Arg1407Leu, XP_011532780.1:p.Arg1401Leu, XP_011532784.1:p.Arg1330Leu, XP_011532785.1:p.Arg1304Leu, XP_011532786.1:p.Arg1171Leu, XR_941095.1:n.4257G>T, rs1309976
C > A
SNP
R1324L
No VIP available CA VA
rs307826 NC_000005.10:g.180624003T>C, NC_000005.9:g.180051003T>C, NG_011536.1:g.30622A>G, NM_002020.4:c.1480A>G, NM_182925.4:c.1480A>G, NP_002011.2:p.Thr494Ala, NP_891555.2:p.Thr494Ala, XM_011534477.1:c.1729A>G, XM_011534478.1:c.1711A>G, XM_011534479.1:c.1729A>G, XM_011534480.1:c.1729A>G, XM_011534481.1:c.1729A>G, XM_011534482.1:c.1498A>G, XM_011534483.1:c.1420A>G, XM_011534484.1:c.1021A>G, XP_011532779.1:p.Thr577Ala, XP_011532780.1:p.Thr571Ala, XP_011532781.1:p.Thr577Ala, XP_011532782.1:p.Thr577Ala, XP_011532783.1:p.Thr577Ala, XP_011532784.1:p.Thr500Ala, XP_011532785.1:p.Thr474Ala, XP_011532786.1:p.Thr341Ala, XR_941095.1:n.1741A>G, rs1309989
T > C
SNP
T494A
No VIP available No Clinical Annotations available VA
rs35597368 NC_000004.11:g.55139771T>C, NC_000004.12:g.54273604T>C, NG_009250.1:g.49508T>C, NM_006206.4:c.1432T>C, NP_006197.1:p.Ser478Pro, XM_005265743.1:c.1432T>C, XM_005265744.1:c.1432T>C, XM_006714039.2:c.1507T>C, XM_006714041.2:c.1507T>C, XM_011534385.1:c.1432T>C, XM_011534386.1:c.1432T>C, XP_005265800.1:p.Ser478Pro, XP_005265801.1:p.Ser478Pro, XP_006714102.1:p.Ser503Pro, XP_006714104.1:p.Ser503Pro, XP_011532687.1:p.Ser478Pro, XP_011532688.1:p.Ser478Pro, rs62619886
T > C
SNP
S478P
No VIP available No Clinical Annotations available VA
rs3814055 NC_000003.11:g.119500035C>T, NC_000003.12:g.119781188C>T, NG_011856.1:g.5705C>T, NM_003889.3:c.-1135C>T, NM_022002.2:c.-1570C>T, NM_033013.2:c.-1135C>T, XM_005247866.1:c.-1300C>T, rs60667929
C > T
SNP
No VIP available No Clinical Annotations available VA
rs4073 NC_000004.11:g.74606024A>T, NC_000004.12:g.73740307A>T, NG_029889.1:g.4802A>T, NM_000584.3:c.-352A>T
A > T
SNP
No VIP available No Clinical Annotations available VA
rs4073054 NC_000001.10:g.161200487C>A, NC_000001.11:g.161230697C>A, NG_029113.1:g.12514G>T, NM_001077469.2:c.932+116G>T, NM_001077470.2:c.713+116G>T, NM_001077471.2:c.800+116G>T, NM_001077472.2:c.845+116G>T, NM_001077473.2:c.857+116G>T, NM_001077474.2:c.800+116G>T, NM_001077475.2:c.713+116G>T, NM_001077476.2:c.845+116G>T, NM_001077477.2:c.830+116G>T, NM_001077478.2:c.929+116G>T, NM_001077479.2:c.830+116G>T, NM_001077480.2:c.929+116G>T, NM_001077481.2:c.815+116G>T, NM_001077482.2:c.944+116G>T, NM_001286373.1:c.*1602C>A, NM_001286374.1:c.*1602C>A, NM_005122.4:c.917+116G>T, NM_032174.5:c.*1602C>A, XM_005245536.1:c.*1602C>A, XM_005245537.1:c.*1602C>A, XM_005245538.1:c.*1602C>A, XM_005245693.1:c.1160+116G>T, XM_005245693.3:c.1160+116G>T, XM_005245694.1:c.1145+116G>T, XM_005245694.3:c.1145+116G>T, XM_005245695.1:c.1031+116G>T, XM_005245696.1:c.1058+116G>T, XM_005245697.1:c.932+116G>T, XM_005245697.3:c.932+116G>T, XM_005245698.1:c.*46+116G>T, XM_005245699.1:c.*46+116G>T, XM_006711572.1:c.*1602C>A, XM_011510057.1:c.*1602C>A, XM_011510237.1:c.1031+116G>T, rs17393733, rs386590491, rs56504295, rs57597870
C > A
SNP
No VIP available CA VA
rs6785049 NC_000003.11:g.119533733G>A, NC_000003.12:g.119814886G>A, NG_011856.1:g.39403G>A, NM_003889.3:c.795-93G>A, NM_022002.2:c.912-93G>A, NM_033013.2:c.684-93G>A, XM_005247866.1:c.630-93G>A, rs58368790
G > A
SNP
No VIP available CA VA
rs699947 NC_000006.11:g.43736389A>C, NC_000006.12:g.43768652A>C, NG_008732.1:g.3437A>C, NM_001025366.2:c.-2055A>C, NM_001025367.2:c.-2055A>C, NM_001025368.2:c.-2055A>C, NM_001025369.2:c.-2055A>C, NM_001025370.2:c.-2055A>C, NM_001033756.2:c.-2055A>C, NM_001171622.1:c.-2055A>C, NM_001171623.1:c.-2595A>C, NM_001171624.1:c.-2595A>C, NM_001171625.1:c.-2595A>C, NM_001171626.1:c.-2595A>C, NM_001171627.1:c.-2595A>C, NM_001171628.1:c.-2595A>C, NM_001171629.1:c.-2595A>C, NM_001171630.1:c.-2595A>C, NM_001204384.1:c.-2595A>C, NM_001204385.1:c.-2055A>C, NM_001317010.1:c.-2595A>C, NM_003376.5:c.-2055A>C, rs1310065, rs36208051, rs61399354
A > C
SNP
No VIP available CA VA
rs776746 NC_000007.13:g.99270539C>T, NC_000007.14:g.99672916T>C, NG_007938.1:g.12083G=, NG_007938.1:g.12083G>A, NM_000777.4:c.219-237A>G, NM_000777.4:c.219-237G>A, NM_001190484.2:c.219-237A>G, NM_001190484.2:c.219-237G>A, NM_001291829.1:c.-253-1A>G, NM_001291829.1:c.-253-1G>A, NM_001291830.1:c.189-237A>G, NM_001291830.1:c.189-237G>A, NR_033807.2:n.717-1A>G, NR_033807.2:n.717-1G>A, NR_033808.1:n.689-1G>A, NR_033809.1:n.581-237G>A, NR_033810.1:n.689-1G>A, NR_033811.1:n.321-1G>A, NR_033812.1:n.321-1G>A, XM_005250169.1:c.189-237G>A, XM_005250170.1:c.-357-1G>A, XM_005250171.1:c.-253-1G>A, XM_005250172.1:c.-254G>A, XM_005250173.1:c.-331-237G>A, XM_005250198.1:c.806-4288C>T, XM_006715859.2:c.219-237A>G, XM_011515843.1:c.-254A>G, XM_011515844.1:c.-229-237A>G, XM_011515845.1:c.-463-1A>G, XM_011515846.1:c.-331-237A>G, XM_011515847.1:c.-571-1A>G, XR_927383.1:n.344-237A>G, XR_927402.1:n.1466+48736T>C, rs10361242, rs11266830, rs386613022, rs58244770
C > T
SNP
No VIP available CA VA
rs833061 NC_000006.11:g.43737486C>T, NC_000006.12:g.43769749C>T, NG_008732.1:g.4534C>T, NM_001025366.2:c.-958C>T, NM_001025367.2:c.-958C>T, NM_001025368.2:c.-958C>T, NM_001025369.2:c.-958C>T, NM_001025370.2:c.-958C>T, NM_001033756.2:c.-958C>T, NM_001171622.1:c.-958C>T, NM_001171623.1:c.-1498C>T, NM_001171624.1:c.-1498C>T, NM_001171625.1:c.-1498C>T, NM_001171626.1:c.-1498C>T, NM_001171627.1:c.-1498C>T, NM_001171628.1:c.-1498C>T, NM_001171629.1:c.-1498C>T, NM_001171630.1:c.-1498C>T, NM_001204384.1:c.-1498C>T, NM_001204385.1:c.-958C>T, NM_001317010.1:c.-1498C>T, NM_003376.5:c.-958C>T, rs36208046, rs60746584
C > T
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • SU11248
  • Sunitinib malate
  • Sutent
Trade Names
  • SU-11248
  • sunitinib
Brand Mixture Names

PharmGKB Accession Id

PA162372840

Type(s):

Drug

Description

Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.

Source: Drug Bank

Indication

For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Sunitinib is a small molecule that inhibits multiple RTKs, some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFRa and PDGFRb), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.

Source: Drug Bank

Pharmacology

Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA on January 26, 2006.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Sunitinib is metabolized primarily by the cytochrome P450 enzyme, CYP3A4, to produce its primary active metabolite, which is further metabolized by CYP3A4.

Source: Drug Bank

Protein Binding

Binding of sunitinib and its primary metabolite to human plasma protein in vitro was 95% and 90%, respectively.

Source: Drug Bank

Absorption

Maximum plasma concentrations (Cmax) of sunitinib are generally observed between 6 and 12 hours (Tmax) following oral administration. Food has no effect on the bioavailability of sunitinib. Sunitinib may be taken with or without food.

Source: Drug Bank

Half-Life

Following administration of a single oral dose in healthy volunteers, the terminal half-lives of sunitinib and its primary active metabolite are approximately 40 to 60 hours and 80 to 110 hours, respectively.

Source: Drug Bank

Clearance

  • Oral cl=34 - 62 L/h

Source: Drug Bank

Route of Elimination

Sunitinib is metabolized primarily by the cytochrome P450 enzyme, CYP3A4, to produce its primary active metabolite, which is further metabolized by CYP3A4. Elimination is primarily via feces. In a human mass balance study of [14C]sunitinib, 61% of the dose was eliminated in feces, with renal elimination accounting for 16% of the administered dose.

Source: Drug Bank

Volume of Distribution

  • 2230 L

Source: Drug Bank

Chemical Properties

Chemical Formula

C22H27FN4O2

Source: Drug Bank

Isomeric SMILES

CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)F)C

Source: OpenEye

Canonical SMILES

CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C

Source: Drug Bank

Average Molecular Weight

398.4738

Source: Drug Bank

Monoisotopic Molecular Weight

398.211804333

Source: Drug Bank

SMILES

CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C

Source: Drug Bank

InChI String

InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. VEGF Signaling Pathway
    Model endothelial cell displaying genes of the VEGF signalling pathway and the sites at which bevacizumab, sorafenib, sunitinib, brivanib and cilengitide are known to act.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
CSF1R (source: Drug Bank )
FLT1 (source: Drug Bank )
FLT3 (source: Drug Bank )
FLT4 (source: Drug Bank )
KDR (source: Drug Bank )
KIT (source: Drug Bank )
PDGFRA (source: Drug Bank )
PDGFRB (source: Drug Bank )
RET (source: Drug Bank )

Drug Interactions

Interaction Description
atazanavir - sunitinib Possible increase in sunitinib levels (source: Drug Bank )
atazanavir - sunitinib Possible increase in sunitinib levels (source: Drug Bank )
carbamazepine - sunitinib Possible decrease in sunitinib levels (source: Drug Bank )
carbamazepine - sunitinib Possible decrease in sunitinib levels (source: Drug Bank )
clarithromycin - sunitinib Possible increase in sunitinib levels (source: Drug Bank )
clarithromycin - sunitinib Possible increase in sunitinib levels (source: Drug Bank )
dexamethasone - sunitinib Possible decrease in sunitinib levels (source: Drug Bank )
dexamethasone - sunitinib Possible decrease in sunitinib levels (source: Drug Bank )
indinavir - sunitinib Possible increase in sunitinib levels (source: Drug Bank )
indinavir - sunitinib Possible increase in sunitinib levels (source: Drug Bank )
itraconazole - sunitinib Possible increase in sunitinib levels (source: Drug Bank )
itraconazole - sunitinib Possible increase in sunitinib levels (source: Drug Bank )
ketoconazole - sunitinib Possible increase in sunitinib levels (source: Drug Bank )
ketoconazole - sunitinib Possible increase in sunitinib levels (source: Drug Bank )
nefazodone - sunitinib Possible increase in sunitinib levels (source: Drug Bank )
nefazodone - sunitinib Possible increase in sunitinib levels (source: Drug Bank )
nelfinavir - sunitinib Possible increase in sunitinib levels (source: Drug Bank )
nelfinavir - sunitinib Possible increase in sunitinib levels (source: Drug Bank )
phenobarbital - sunitinib Possible decrease in sunitinib levels (source: Drug Bank )
phenobarbital - sunitinib Possible decrease in sunitinib levels (source: Drug Bank )
phenytoin - sunitinib Possible decrease in sunitinib levels (source: Drug Bank )
phenytoin - sunitinib Possible decrease in sunitinib levels (source: Drug Bank )
rifabutin - sunitinib Possible decrease in sunitinib levels (source: Drug Bank )
rifabutin - sunitinib Possible decrease in sunitinib levels (source: Drug Bank )
rifampin - sunitinib Possible decrease in sunitinib levels (source: Drug Bank )
rifampin - sunitinib Possible decrease in sunitinib levels (source: Drug Bank )
telithromycin - sunitinib Possible increase in sunitinib levels (source: Drug Bank )
telithromycin - sunitinib Telithromycin may reduce clearance of Sunitinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sunitinib if Telithromycin is initiated, discontinued or dose changed. (source: Drug Bank )
thiothixene - sunitinib May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank )
thiothixene - sunitinib May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank )
topotecan - sunitinib The p-glycoprotein inhibitor, Sunitinib, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. (source: Drug Bank )
toremifene - sunitinib Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank )
trastuzumab - sunitinib Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. (source: Drug Bank )
trimipramine - sunitinib Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. (source: Drug Bank )
voriconazole - sunitinib Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sunitinib by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of sunitinib if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
vorinostat - sunitinib Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
ziprasidone - sunitinib Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated. (source: Drug Bank )
zuclopenthixol - sunitinib Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )

Curated Information ?

EvidenceDisease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Acute coronary syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Anemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Anorexia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arrhythmias, Cardiac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arthritis, Rheumatoid
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Asthenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Atrial Fibrillation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Attention Deficit Disorder with Hyperactivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bipolar Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breast Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carcinoma, Non-Small-Cell Lung
No Dosing Guideline available DL CA VA No VIP available No VIP available
Carcinoma, Renal Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Colorectal Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Crohn Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Depression
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
Diarrhea
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Drug Toxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dyspnea
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epilepsy
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Esophagitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Exanthema
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Fatigue
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Fever
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gastrointestinal Stromal Tumors
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
hand-foot syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Headache
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Heart Failure
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hereditary Breast/Ovarian Cancer Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HIV Infections
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypercholesterolemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypereosinophilic Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperglycemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperlipoproteinemia Type II
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypokalemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypothyroidism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inflammatory Bowel Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Kidney Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Lymphocytic, Chronic, B-Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myeloid, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Nonlymphocytic, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Promyelocytic, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Leukopenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lung Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lymphopenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Malaria
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
mucositis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Myalgia unspecified
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mycoses
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Myelodysplastic Syndromes
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Nausea
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Neoplasm Metastasis
No Dosing Guideline available DL CA VA No VIP available No VIP available
Neoplasms
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
Neutropenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ocular Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ovarian Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
overall survival
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pain
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Palmar-plantar erythrodysaesthesia syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Precursor Cell Lymphoblastic Leukemia-Lymphoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
progression-free survival
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pulmonary Disease, Chronic Obstructive
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pulmonary Fibrosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Schizophrenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sjogren's Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stomatitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stroke
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Thrombocytopenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Thromboembolism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Toxic liver disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tuberculosis, Pulmonary
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tumor Lysis Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Urinary Incontinence
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ventricular Dysfunction, Left
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vomiting

Publications related to sunitinib: 39

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen. Cancer chemotherapy and pharmacology. 2016. Chae Jung-Woo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine. Pharmacogenomics. 2016. De Mattia Elena, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma. European urology. 2015. Diekstra Meta H M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. European journal of clinical pharmacology. 2015. Diekstra Meta H M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Serum C-telopeptide collagen crosslinks and plasma soluble VEGFR2 as pharmacodynamic biomarkers in a trial of sequentially administered sunitinib and cilengitide. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015. O'Donnell Peter H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. British journal of cancer. 2015. Xu C-F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. The pharmacogenomics journal. 2015. Teo Y L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Investigational new drugs. 2015. Narjoz C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. PloS one. 2015. Chu Ying-Hsia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer chemotherapy and pharmacology. 2014. Motzer Robert J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clinical pharmacology and therapeutics. 2014. Diekstra M H M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
EMA Initiatives and Perspectives on Pharmacogenomics. British journal of clinical pharmacology. 2014. Ehmann Falk, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer chemotherapy and pharmacology. 2013. Kim Hye Ryun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update. Pharmacogenomics. 2013. Eng Lawson, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. British journal of cancer. 2013. Beuselinck B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics. 2013. Jensen Brian C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clinical pharmacology and therapeutics. 2012. Eechoute K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenetics and genomics. 2012. Lamba Jatinder, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. The lancet oncology. 2011. Garcia-Donas Jesus, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clinical pharmacokinetics. 2011. Di Gion Paola, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta oncologica (Stockholm, Sweden). 2011. Bono Petri, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. Gangadhar Tara C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. van der Veldt Astrid A M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clinical pharmacology and therapeutics. 2010. Lindauer A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vascular endothelial growth factor pathway. Pharmacogenetics and genomics. 2010. Maitland Michael L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evolving novel anti-HER2 strategies. The lancet oncology. 2009. Jones Kellie L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Houk Brett E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gastrointestinal stromal tumor: a clinical overview. Hematology/oncology clinics of North America. 2009. Quek Richard, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proceedings of the National Academy of Sciences of the United States of America. 2009. Gajiwala Ketan S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008. Schmidinger Manuela, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008. Heinrich Michael C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. British journal of cancer. 2008. van der Veldt A A M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clinical therapeutics. 2007. Adams Val R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. Journal of the National Cancer Institute. 2007. Rini Brian I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (London, England). 2006. Demetri George D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006. Motzer Robert J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006. Faivre Sandrine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003. Mendel Dirk B, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0069-0550-38
DrugBank:
DB01268
PDB:
B49
ChEBI:
38940
KEGG Drug:
D06402
PubChem Compound:
5329102
PubChem Substance:
14830382
46507140
Drugs Product Database (DPD):
2280795
BindingDB:
4814
ChemSpider:
4486264
HET:
B49
Therapeutic Targets Database:
DCL000646
FDA Drug Label at DailyMed:
43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c

Clinical Trials

These are trials that mention sunitinib and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.